Invasive Decoding and Stimulation of Altered Reward Computations in Depression
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Feb 4, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring new ways to treat major depressive disorder using advanced brain stimulation techniques. Researchers are specifically looking at areas of the brain that help control mood and decision-making. By studying brain activity in patients with epilepsy who are already receiving treatment, the team hopes to identify unusual brain responses related to depression. This information could help develop new treatments that stimulate the brain to improve mood and decision-making.
To participate in this study, you need to be an adult between 18 and 80 years old who is undergoing invasive monitoring for epilepsy. The study is currently recruiting participants, and both men and women are welcome. If you join, you can expect to have your brain activity monitored while you make choices, which will help researchers understand how depression affects brain function. This research could lead to innovative therapies for those struggling with depression.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - The study will follow clinical criteria for epilepsy patient recruitment for invasive monitoring. As a results, individuals of adults of all ages are expected to be included in this study.
- Exclusion Criteria:
- • Adults over 80 years of age will be excluded as per concerns of cognitive decline.
- • Children under 18 will be excluded from the study since the maturation of frontal lobes continues through adolescence and significant differences in frontal lobe functioning between children younger than 18 and adults are often observed.
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Ignacio Saez, Ph.D.
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials